|
|
| Year : 2017 | Volume
: 23
| Issue : 2 | Page : 127 |
|
| Finally, it is bismuth's time |
|
|
Davide G Ribaldone1, Giorgio Saracco2, Rinaldo Pellicano3
1 General and Specialist Medicine Department, Città della Salute e della Scienza of Turin, Turin, Italy
2 Department of Oncology, University of Torino, Torino, Italy
3 Department of Gastroenterology, Molinette Hospital, Turin, Italy
Click here for correspondence address and email
| Date of Web Publication | 29-Mar-2017 |
|
|
 |
|
How to cite this article:
Ribaldone DG, Saracco G, Pellicano R. Finally, it is bismuth's time. Saudi J Gastroenterol 2017;23:127 |
Sir,
In an interesting Turkish retrospective study, conducted between 2012 and 2015, involving 1510 adults, Kekilli et al.[1] tested triple therapy (lansoprazole 30 mg b.i.d., clarithromycin 500 mg b.i.d., and amoxicillin 1 g b.i.d.), bismuth group C (lansoprazole, clarithromycin, amoxicillin, and bismuth subsalicylate 524 mg b.i.d.), and bismuth group M (lansoprazole, amoxicillin, metronidazole 500 mg t.i.d., and bismuth) for 14 days as first line treatment for Helicobacter pylory infection. H. pylori eradication was achieved in (per-protocol analysis) 64.7% of the patients in the triple therapy group, 95.4% in the bismuth group C, and 93.9% in the bismuth group M. Intolerable side effects leading to interruption of therapy were rare (approximately 2–3%) and similar in the different groups.
These results are in agreement with the recently published Maastricht V Consensus Report,[2] and confirmed that clarithromycin-based triple therapy should be abandoned when the clarithromycin resistance rate is more than 15%. In regions with high clarithromycin resistance but low-to-intermediate metronidazole resistance (<40%), 14 days bismuth quadruple therapy is advised as first line treatment.[3]
In Turkey, the H. pylori clarithromycin resistance is 16.3–50% whereas metronidazole resistance is 39.2%.[2]
In 2012, in Piedmont, Northern Italy, a region with the same H. pylori antibiotic resistance of Turkey, we [4] have prospectively evaluated the H. pylori eradication rate of 182 consecutive naive patients treated with a clarithromycin-based triple therapy: The eradication rate was 73.4%, which is considered unacceptable.[5]
In conclusion, the study conducted by Kekilli et al.[1] reaffirm that triple therapy now has an unacceptable eradication failure rate and it should no more be the first choice in countries with a high H. pylori resistance rate to clarithromycin. In this context, now is the era of bismuth-based quadruple therapy as first line treatment. When available, this could be prescribed as the new formulation with bismuth, metronidazole, and tetracycline contained in a single capsule (three-in-one).[3]
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
 References | |  |
| 1. | Kekilli M, Onal IK, Ocal S, Dogan Z, Tanoglu A. Inefficacy of triple therapy and comparison of two different bismuth-containing quadruple regimens as a firstline treatment option for helicobacter pylori. Saudi J Gastroenterol 2016;22:366-9.  [ PUBMED] [Full text] |
| 2. | Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2016. pii: Gutjnl-2016-312288. |
| 3. | Pellicano R, Ribaldone DG, Fagoonee S, Astegiano M, Saracco GM, Mégraud F. A 2016 panorama of Helicobacter pylori infection: Key messages for clinicians. Panminerva Med 2016;58:304-17. |
| 4. | Ribaldone DG, Fagoonee S, Astegiano M, Saracco G, Pellicano R. Efficacy of amoxycillin and clarithromycin-based triple therapy for Helicobacter pylori eradication: A 10-year trend in Turin, Italy. Panminerva Med 2015;57:145-6. |
| 5. | Gisbert JP, Calvet X, O'Connor A, Mégraud F, O'Morain CA. Sequential therapy for Helicobacter pylori eradication: A critical review. J Clin Gastroenterol 2010;44:313-25. |
Correspondence Address:
Davide G Ribaldone
General and Specialist Medicine Department, Città della Salute e della Scienza of Turin, Turin
Italy
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/sjg.SJG_605_16
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Article Access Statistics | | | Viewed | 1355 | | | Printed | 32 | | | Emailed | 0 | | | PDF Downloaded | 128 | | | Comments | [Add] | | |
|
|
